Drug intelligence / Profile preview

SNP210

Development stage: Preclinical
Lead developer: SciNeuro Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SNP210 is a human autoantibody developed by SciNeuro Pharmaceuticals for the treatment of neurodegenerative diseases, specifically Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The drug targets TAR DNA-binding protein 43 (TDP-43), a protein that forms pathological aggregates in the central nervous system of patients with these conditions. By targeting TDP-43, SNP210 is designed to mitigate the proteinopathy associated with disease progression. It is currently in preclinical development.

Other names: SNP210SNP-210SNP 210

Targets

TARDBP (TAR DNA-binding protein 43)

Beyond the preview

Go deeper on SNP210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNP210.

Explore the full profile